Eiger Mountains
Keyword Search
 
2017 | 2016
DateTitle 
05/17/17Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
- Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in which modulation of the inflammatory mediator, leukotriene B4 (LTB4), improved experimental lymphedema.  Targeted reduction of LTB4 with ubenimex reversed edema, improved lymphatic function and restored... 
Printer Friendly Version
05/15/17Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
- Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 LIBERTY study.  The LIBERTY study is designed to evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH).  Ubenimex is a well-characterized, ora... 
Printer Friendly Version
05/12/17Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
- Five Phase 2 Programs in Four Orphan Indications Progressing - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., May 12, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months ended March 31, 2017 and provided a business update. "Building on our achievements in 20... 
Printer Friendly Version
05/08/17Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
PALO ALTO, Calif., May 8, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in Chicago, Illinois.  Results from two longitudinal patient databases showed a consistently growing number of newly diagnosed HDV patients in the US and a markedly higher than previously estimated incidence of HDV co-infection among chronic HBV p... 
Printer Friendly Version
05/04/17Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
- Phase 2 LIBERTY Study Update for Ubenimex in PAH PALO ALTO, Calif., May 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, will host a key opinion leader lunch to address the need for novel mechanisms in the treatment of pulmonary arterial hypertension (PAH), promising preclinical research identifying the potential for disease modification in PAH, and new classes of investigational... 
Printer Friendly Version
05/03/17Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling PALO ALTO, Calif., May 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the U.S. IND has been filed for Pegylated Interferon Lambda in the treatment of hepatitis delta virus (HDV) infection.  U.S. sites are planned for the ongoing Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a m... 
Printer Friendly Version
04/24/17Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
PALO ALTO, Calif., April 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois, May 6 to 9, 2017. Accepted DDW abstract is listed below: Martins, EB and Glenn, JS; "Prevalence of Hepatitis Delta Virus (HDV) Infection in the United States: Results from an ICD-10 Review";... 
Printer Friendly Version
04/21/17Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
PALO ALTO, Calif., April 21, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver Congress™ 2017, in Amsterdam, Netherlands.  After 24 weeks of treatment, all-oral lonafarnib-based regimens (LNF 25 mg or 50 mg BID + Ritonavir, or RTV) suppressed HDV-RNA below the limit of quantitation in 36% ... 
Printer Friendly Version
04/18/17Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
- Novel Liquid Formulation of Exendin 9-39 Advancing PALO ALTO, Calif., April 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the appointment of Lisa Porter, M.D. to lead the development of exendin 9-39 for the treatment of post-bariatric hypoglycemia (PBH).  "Dr. Porter brings over 15 years of experience in developing medicines for di... 
Printer Friendly Version
04/06/17Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif., April 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, Netherlands , April 19 to 23, 2017.  Forty-eight week data from the Phase 2 LOWR HDV Program will be presented. Accepted EASL abstracts are listed below: Wedemeyer, H. et al; "... 
Printer Friendly Version
03/23/17Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
- Five Phase 2 Programs in Four Orphan Indications - Multiple Value-Creating Events Across Programs Expected in Next 12-18 Months PALO ALTO, Calif., March 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months and full year ended December 31, 2016. "We believe that 2016, Eiger's first year as a publ... 
Printer Friendly Version
01/30/17Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
PALO ALTO, Calif., Jan. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City.  A live webcast ... 
Printer Friendly Version
01/04/17Eiger Completes $25 Million Debt Financing with Oxford Finance
PALO ALTO, Calif., Jan. 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide.  Proceeds of the financing are intended for use to advance Eiger's diverse pipeline of clinical ... 
Printer Friendly Version
01/03/17Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif., Jan. 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that the first patient has completed 24 weeks dosing in the double-blind Phase 2 LIBERTY study and has now received treatment with ubenimex in the open-label extension. LIBERTY is a randomized, double-blind, placebo-controlled study ... 
Printer Friendly Version